4/A: MAIA Biotechnology Director Ramiro Guerrero Amends Form 4 Filing to Correct Dates

Ramiro Guerrero, a director at MAIA Biotechnology, Inc., filed an amended Form 4 to correct the exercisable and expiration dates of warrants and the date of the Securities Purchase Agreement.

Summary

• Ramiro Guerrero, a director of MAIA Biotechnology, Inc., filed an amendment (Form 4/A) to a previously filed Form 4.
• The amendment corrects the 'Date Exercisable' and 'Expiration Date' of warrants reported in Table II of the original filing.
• The amendment also corrects the date of the Securities Purchase Agreement referenced in footnotes 1 and 2 to February 24, 2025.
• On February 24, 2025, Guerrero purchased 73,333 shares of common stock at $1.50 per share, bringing his total direct holdings to 534,885.04 shares.
• He also purchased 73,333 warrants with an exercise price of $1.87, exercisable from February 25, 2026, and expiring on February 25, 2031.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting previously reported information. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to insider transactions and is required by the SEC to ensure transparency in the market.

Stakeholder Impact

• The correction of information ensures transparency for shareholders.

Key Dates